TITLE:
Multicenter Trial for Adults With Partial Seizures

CONDITION:
Epilepsy

INTERVENTION:
Talampanel

SUMMARY:

      To compare seizure frequency in patients with refactory partial seizures (with or without
      generalization) who are taking Talampanel versus placebo as an add-on therapy to other
      licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in
      this group of patients.
    

DETAILED DESCRIPTION:

      A randomized, double-blind, placebo controlled, multicenter, efficacy and safety study of
      talampanel (TLP) in 190 patients (18-65 years old) with refractory partial seizures.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        Inclusion Criteria:

          -  must weigh greater than or equal to 40kg

          -  Patients must have diagnosis of partial seizures

          -  At least 3 observable partial seizures a month

          -  Are currently being treated with 1 and no more than 2 marketed Anti-epileptic Drugs.

        Exclusion:

          -  Patients on Valproic acid, and Felbamate
      
